InvestorsHub Logo
Followers 50
Posts 4419
Boards Moderated 0
Alias Born 03/20/2012

Re: blue finch post# 2038

Wednesday, 02/01/2023 10:21:17 AM

Wednesday, February 01, 2023 10:21:17 AM

Post# of 2139
Alliance Global Partners launched coverage of Hepion Pharmaceuticals (NASDAQ:HEPA) with a “buy” rating and price target of $4. Shares of Hepion closed at 73 cents on Jan. 31.

Analyst James Molloy writes that his recommendation is based primarily on expectations for Hepion’s rencofilstat, a cyclophilin inhibitor that is being developed to treat non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC) associated with NASH.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent HEPA News